Drug Discovery Approaches to Target E3 Ligases
ChemBioChem · 02.01.2025 · 26 (1)
DOI: 10.1002/cbic.202400656 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemBioChem, online erschienen am 17.12.2024. Verfasst von Alejandra Rodríguez-Gimeno und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department de Farmacia I Tecnología Farmacèutica, I Fisicoquímica, Universitat de Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Drug Discovery, Small Molecule Libraries, Enzyme Inhibitors. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministerio de Economía, Industria y Competitividad, European Union, European Commission.
Abstract (Originalsprache)
Targeting E3 ligases is a challenging area in drug discovery. Despite the human genome encoding for more than 600 E3 ubiquitin ligases, only a handful of E3 ligases have been pharmacologically modulated or exploited for targeted protein degradation (TPD) strategies. The main obstacle for hijacking these E3 ligases is the lack of small‐molecule ligands. As research into this field advances, the identification of new small molecules capable of binding to E3 ligases has become an essential pursuit. These ligases not only expand the repertoire of druggable targets but also offer the potential for increased specificity and selectivity in protein degradation. The synergy between academia and industry is key, as it combines academic expertise in fundamental research with the industrial capabilities of translating these findings into novel therapeutics. In this review, we provide an overview of the different strategies employed in academia and industry to the discovery of new E3 ligases ligands, showing them with illustrative cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department de Farmacia I Tecnología Farmacèutica, I Fisicoquímica, Universitat de Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
- Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.
ORCID-Profile: Carles Galdeano
Förderung
- Spanish Ministerio de Economía, Industria y Competitividad
- European Union
- European Commission
Zitieren
APA
Rodríguez-Gimeno, A., & Galdeano, C. (2025). Drug Discovery Approaches to Target E3 Ligases. ChemBioChem, 26(1). https://doi.org/10.1002/cbic.202400656
Vancouver
Rodríguez-Gimeno A, Galdeano C. Drug Discovery Approaches to Target E3 Ligases. ChemBioChem. 2025;26(1). doi:10.1002/cbic.202400656
BibTeX
@article{RodrguezGimeno2025,
author = {Rodríguez-Gimeno, Alejandra and Galdeano, Carles},
title = {Drug Discovery Approaches to Target E3 Ligases},
journal = {ChemBioChem},
year = {2025},
volume = {26},
number = {1},
doi = {10.1002/cbic.202400656}
}
EUVIMED